Deep Brain Stimulation News and Research

RSS

Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms—most commonly the debilitating symptoms of Parkinson’s disease (PD), such as tremor, rigidity, stiffness, slowed movement, and walking problems. The procedure is also used to treat essential tremor, a common neurological movement disorder. At present, the procedure is used only for patients whose symptoms cannot be adequately controlled with medications.

Medtronic DBS Therapy improves motor function in patients with advanced Parkinson's disease: Study

In the largest, randomized, controlled study of deep brain stimulation for Parkinson's disease, Medtronic DBS Therapy was shown to improve motor function for up to two years in patients with advanced Parkinson's disease, showing equally strong efficacy for the two most common surgical targets used for the therapy.

3 Jun 2010

DBS procedure effective for treating Parkinson's disease

Studies have shown that a "brain pacemaker" called deep brain stimulation (DBS) is an effective treatment for Parkinson's disease.

3 Jun 2010

Sticky gel composed of MPEG-pDHA may help seal wounds created by surgery: Study

A compound found in sunless tanning spray may help to heal wounds following surgery, according to new results published by plastic surgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City and biomedical engineers at Cornell University in Ithaca, N.Y., where the novel compound was developed.

1 Jun 2010

Deep-brain stimulation makes difference in the lives of people with Parkinson disease

A surgical treatment that stimulates distressed neural networks through electrodes threaded directly into a person's brain has quietly made a difference in the lives of tens of thousands of people with Parkinson disease, essential tremor, and dystonia over the course of the past decade. But while it steadies patients' shaking limbs with surprising effect, its benefits on some patients' minds and personal lives have been more mixed.

31 May 2010

Hebrew Union College honors Dr. Dean Lorich with 2010 Roger E. Joseph Prize for humanitarian efforts

Dr. Dean Lorich was honored with the 2010 Roger E. Joseph Prize by Hebrew Union College for his humanitarian efforts in treating victims of the recent Haiti earthquake and in Landstuhl, Germany treating soldiers injured in Iraq and in Afghanistan. The award recognizes individuals making lasting contributions to the causes of human rights.

29 May 2010

St. Jude Medical's Epiducer lead delivery system for neurostimulation therapy receives CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its new Epiducer™ lead delivery system for neurostimulation therapy. Unveiled at the Neurosurgery 2010 Congress in Lyon, France, the Epiducer lead delivery system is the first of its kind, allowing introduction of S-Series perc-paddle leads as well as multiple lead arrays through a single percutaneous entry point.

27 May 2010

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Weill Cornell Medical College today celebrated the start of construction on its new Medical Research Building, a state-of-the-art facility that will more than double the institution's existing research space. The 18-story, $650 million building is the centerpiece of Weill Cornell's $1.3 billion Discoveries that Make a Difference Campaign, the country's largest for a medical college. A total of $1 billion has been raised toward this goal in a record time of less than four years.

27 May 2010

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 30, 2010.

25 May 2010

GHESKIO awarded prestigious 2010 Gates Award for Global Health

GHESKIO, an institution in Haiti founded nearly three decades ago to fight a mysterious killer disease later identified as AIDS, has been awarded the prestigious 2010 Gates Award for Global Health for its years of groundbreaking clinical service, research and training to effectively treat and prevent the spread of the HIV/AIDS and other related illnesses.

19 May 2010

Potential new drug therapies for treatment of tuberculosis

Tuberculosis (TB) has been present in humans since ancient times. The origins of the disease date back to the first domestication of cattle, and skeletal remains show prehistoric humans (4,000 B.C.) had TB. Although relatively rare in the United States, it is the single leading bacterial cause of death worldwide. Approximately 8 million people are infected each year and 2 million people die from TB.

11 May 2010

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

An estimated 26.2 percent of Americans ages 18 and older - about one in four adults - suffer from a diagnosable mental disorder every year, which equates to approximately 57.7 million adults. Severe psychiatric illness affects a much smaller number of people - about 6 percent, or 1 in 17. Worldwide, an estimated 340 million people suffer from an episode of major depression every year.

5 May 2010

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Scientists have shown that through eye examinations, doctors can identify infants who are most likely to benefit from early treatment for a potentially blinding eye condition called retinopathy of prematurity, resulting in better vision for many children.

4 May 2010

Slitrk5 gene linked to development of OCD-like behaviors

Researchers at the Ansary Stem Cell Institute and the Department of Psychiatry at Weill Cornell Medical College discovered that mice missing a single gene developed repetitive obsessive-compulsive-like behaviors. The genetically altered mice, which behaved much like people with a certain type of obsessive-compulsive disorder (OCD), could help scientists design new therapies for this debilitating condition.

27 Apr 2010

New discovery links Slitrk5 gene to development of OCD-like behaviors

27 Apr 2010

Research findings may help personalize use of statins, scientists say

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered why statins -- popular drugs that lower cholesterol and appear to protect against colorectal cancer development -- work for some people, but not for all.

22 Apr 2010

President of Tanzania emphasizes on health care in Global Health Grand Rounds lecture

President Jakaya Kikwete of the United Republic of Tanzania spoke at Weill Cornell Medical College today. In his Global Health Grand Rounds lecture, President Kikwete discussed the most significant challenges facing Tanzania, with a particular focus on health care and the advances made during his first term.

17 Apr 2010

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients over 18 months and significantly reduced the rate of atrophy (shrinkage) of their brains, according to a study performed at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

15 Apr 2010

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

Study: New anti-cancer agents halt cancer metastasis

ke microscopic inchworms, cancer cells slink away from tumors to travel and settle elsewhere in the body. Now, researchers at Weill Cornell Medical College report in today's online edition of the journal Nature that new anti-cancer agents break down the loping gait these cells use to migrate, stopping them in their tracks.

15 Apr 2010

Deep Brain Stimulation News and Research

Further Reading

Medtronic DBS Therapy improves motor function in patients with advanced Parkinson's disease: Study

DBS procedure effective for treating Parkinson's disease

Sticky gel composed of MPEG-pDHA may help seal wounds created by surgery: Study

Deep-brain stimulation makes difference in the lives of people with Parkinson disease

Hebrew Union College honors Dr. Dean Lorich with 2010 Roger E. Joseph Prize for humanitarian efforts

St. Jude Medical's Epiducer lead delivery system for neurostimulation therapy receives CE Mark approval

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

GHESKIO awarded prestigious 2010 Gates Award for Global Health

Potential new drug therapies for treatment of tuberculosis

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Slitrk5 gene linked to development of OCD-like behaviors

New discovery links Slitrk5 gene to development of OCD-like behaviors

Research findings may help personalize use of statins, scientists say

President of Tanzania emphasizes on health care in Global Health Grand Rounds lecture

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Study: New anti-cancer agents halt cancer metastasis

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News